Latest Breaking News On - Faculty of pharmacy at laval university - Page 1 : comparemela.com

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related

Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term use of levodopaPublished preclinical data in widely used MPTP non-human primate model of Parkinson's disease show AV-1.

United statesNate hitchingsMark mcpartlandExchange commissionCanadian intellectual property officeTrademark officeLaval research centerFaculty of pharmacy at laval universityEmeritus professorLaval universityAnnual reportVice presidentInvestor relations

VistaGen Therapeutics (VTGN) Receives Notice of Allowance for AV-101 Canadian Patent

VistaGen Therapeutics (VTGN) Receives Notice of Allowance for AV-101 Canadian Patent
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark mcpartlandNate hitchingsFaculty of pharmacy at laval universityLaval research centerTrademark officeExchange commissionCanadian intellectual property officeEmeritus professorLaval universityAnnual reportVice president

VistaGen Therapeutics (VTGN) Announces Publication in Cells Demonstrating AV-101 s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson s Disease

VistaGen Therapeutics (VTGN) Announces Publication in Cells Demonstrating AV-101 s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson s Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shawn singhTrademark officeFaculty of pharmacy at laval universityLaval research centerWall streetChief executive officerEmeritus professorLaval universityPro drug antagonistGlycine siteReducesl dopa induced dyskinesias